Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Allergy & Immunology
•
Asthma
How do you decide when to add a second biologic agent to a patient’s asthma treatment who has either not responded or had a partial response to dupilumab, omalizumab, mepolizumab, or tezepelumab?
Related Questions
What is your preferred biologic in children and adolescents with T2 high asthma?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
Is methacholine challenge on its way out?
Is there any genetic testing available for the CDHR3 receptor?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Do you utilize urinary leukotrienes as a marker for initiation of montelukast?
Have you observed adverse mental health side effects in patients who start montelukast?
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?